| 摘要 |
Disclosed is the use of a combination of Cladribine and Interferon-beta (IFN-beta) for the manufacture of a medicament for treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis, wherein Cladribine is to be orally administered following the sequential steps below: (i) an induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg; (ii) a Cladribine-free period wherein no Cladribine is administered; (iii) a maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and (iv) a Cladribine-free period wherein no Cladribine is administered.
|
